P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia

Clinical Cancer Research

Volumn 6, Issue 8, 2000, Pages 3205-3214

  Van Der Kolk, Dorina M ^a   De Vries, Elisabeth G E ^a   Van Putten, Wim L J ^b   Verdonck, Leo F ^c   Ossenkoppele, Gert J ^d   Verhoef, Gregor E G ^e   Vellenga, Edo ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; ANTINEOPLASTIC AGENT; CARBOXYFLUORESCEIN; CYTARABINE; DAUNORUBICIN; GLYCOPROTEIN P; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN; RHODAMINE 123; VALSPODAR; VERLUKAST;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER CLASSIFICATION; CANCER REGRESSION; CANCER RESISTANCE; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION FUNCTION; FEMALE; FLOW CYTOMETRY; HIGH RISK POPULATION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ATP-BINDING CASSETTE TRANSPORTERS; CYCLOSPORINS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; FLOW CYTOMETRY; FLUORESCEINS; FLUORESCENT DYES; GLUTATHIONE; HUMANS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; P-GLYCOPROTEIN; PROPIONATES; QUINOLINES; RANDOMIZED CONTROLLED TRIALS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RHODAMINE 123; RNA, MESSENGER; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 0033897693     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Mayer, J. R., Davis, R. B., Schiffer, C. A., Berg, D. T., Powell, B. L., Schulman, P., Omura, G. A., Moore, J. O., McIntyre, O. R., and Frei, E. Third intensive postremission chemotherapy in adults with acute myeloid leukemia. N. Engl. J. Med., 331: 896-903, 1994.
2. Cassileth, P. A., Lynch, E., Hines, J. D., Oken, M. M., Mazza, J. J., Bennet, J. M., McGlare, P. B., Edelstein, M., Harrington, D. P., and O'Connell, M. J. Varying intensity of postremission therapy in acute myeloid leukemia. Blood, 79: 1924-1930, 1993.
3. Schiller, G., Gajewski, J., Territo, M., Nimer, S., Lee, M., Belin, T., and Champlin, R. Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia. Blood, 80: 2977-2982, 1992.
4. Cassileth, P. A., Harrington, D. P., Appelbaum, F. R., Hillard, M. L., Rowe, J. M., Paiette, E., Willman, C., Hurd, D. D., Bennett, J. M., Blume, K. G., Head, D. R., and Wiernik P. H. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N. Engl. J. Med., 339: 1649-1656.
5. Godwin, J. E., Kopecky, K. J., Head, D. R., Willman, C. L., Leith, C. P., Hynes, H. E., Balcerzak, S. P., and Appelbaum, F. R. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group Study (9031). Blood, 15: 3607-3615, 1998.
6. Löwenberg, B., Van Putten, W. L. J., Verdonck, L. F., Dekker, A. W., De Gast, C. G., Willemze, R., Zwaan, F. E., De Planque, H., Abels, J., Sonneveld, P., Van der Lelie, J., Goudsmit, R., Sizoo, W., and Hagenbeek, A. Autologous bone marrow transplantation in acute myeloid leukemia in first remission: results of a Dutch prospective study. J. Clin. Oncol., 8: 287-294, 1990.
7. Burnett, A. K., Transey, P., Watkins, R., Alcorn, M., Maharaj, D., Singer, C. R., McKinnon, S., McDonald, G. A., and Robertson, A. G. Transplantation of unpurged autologous bone-marrow in acute myeloid leukaemia in first remission. Lancet, 2: 1068-1070, 1984.
8. Simon, M., and Schindler, M. Cell biological mechanisms of multidrug resistance in tumor. Proc. Natl. Acad. Sci. USA, 91: 3497-3504, 1994.
9. Germann, U. A. Molecular analysis of P-glycoprotein. Eur. J. Cancer, 32A: 927-944, 1996.
10. Marie, J-P., Zittoun, R., and Sikic, B. I. Multidrug resistance (MDR1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood, 78: 586-592, 1991.
11. Campos, L., Guyotat, D., Archimbaud, E., Calmard-Oriol, P., Tsuruo, T., Troncy, J., Treille, D., and Fiere, D. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood, 79: 473-476, 1992.
12. Guerci, A., Merlin, H. L., Missoun, N., Feldmann, L., Marchal, S., Witz, F., Rose, C., and Guerci, O. Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry. Blood, 85: 2147-2153, 1995.
13. Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V., and Deeley, R. G. Overexpression of a novel transporter gene in a multidrug resistant human lung cancer cell line. Science (Washington DC), 258: 1650-1654, 1992.
14. Taniguchi, K., Wada, M., Kohno, K., Nakamura, T., Kawabe, T., Kawakami, M., Kagotani, K., Okumura, K., Akiyama, S., and Kuwano, M. A human canalicular multispecific anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res., 56: 4124-4129, 1996.
15. Grant, C. E., Valdimarsson, G., Hipfner, D. R., Almquist, K. C., Cole, S. P. C., and Deeley, R. G. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res., 54: 357-361, 1994.
16. r 190,000 multidrug resistance protein (MRP): evidence for cotransport with reduced glutathione. Cancer Res., 58: 5130-5136, 1998.
17. Schinkel, A. H., Mayer, U., Wagenaar, E., Mol, C. A., van Deemter, L., Smit, J. J., van der Valk, M. A., Voordouw, A. C., Spits, H., van Tellingen, O., Zijlmans, J. M., Fibbe, W. E., and Borst, P. Normal viability and altered pharmacokinetics in mice lacking the mdr1 type (drug-transporting) P-glycoprotein. Proc. Natl. Acad. Sci. USA, 94: 4028-4033, 1997.
18. Marbeuf-Gueye, C., Broxterman, H. J., Dubru, F., Priebe, W., and Garnier-Suillerot, A. Kinetics of anthracycline efflux from multidrug resistance protein-expressing cancer cells compared with P-glycoprotein-expressing cancer cells. Mol. Pharmacol., 53: 141-147, 1998.
19. Müller, M., Meyer, C., Zaman, G. J., Borst, P., Scheper, R. J., Mulder, N. H., de Vries, E. G. E., and Jansen, P. L. M. Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc. Natl. Acad. Sci. USA, 91: 13033-13037, 1994.
20. Loe, D. W., Almquist, K. C., Deeley, R. G., and Cole, S. P. C. Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles: demonstration of glutathione-dependent vincristine transport. J. Biol. Chem., 271: 9675-9682, 1996.
21. Renes, J., de Vries, E. G. E., Nienhuis, E. F., Jansen, P. L. M., and Müller, M. ATP- and glutathione-dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1. Br. J. Pharmacol., 126: 681-688, 1999.
22. Leier, J., Jedlitschky, G., Buchholz, U., Cole, S. P. C., Deeley, R. G., and Keppler, D. The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related agents. J. Biol. Chem., 269: 27807-27810, 1994.
23. Van der Kolk, D. M., de Vries, E. G. E., Koning, J. A., Van den Berg, E., Muller, M., and Vellenga, E. Activity and expression of the multidrug resistance proteins MRP1 and MRP2 in acute myeloid leukemia cells, tumor cell lines and normal hematopoietic CD34+ peripheral blood cells. Clin. Cancer Res., 4: 1727-1736, 1998.
24. Hart, S. M., Ganeshaguru, K., Hoffbrand, A. V., Prentice, H. G., and Mehta, A. B. Expression of the multidrug resistance-associated protein (MRP) in acute leukaemia. Leukemia, 8: 2163-2168, 1994.
25. Zhou, D. C., Zittoun, R., and Marie, J-P. Expression of multidrug resistance-associated protein (MRP) and multidrug resistance (MDR1) genes in acute myeloid leukemia. Leukemia (Baltimore), 9: 1661-1666, 1995.
26. Te Boekhorst, P. A., Löwenberg B., van Kapel, J., Nooter, K., and Sonneveld, P. Multidrug resistant cells with high proliferative capacity determine response to therapy in acute myeloid leukemia. Leukemia (Baltimore), 9: 1025-1031, 1995.
27. Schneider, E., Cowan, K. H., Bader, H., Toomey, S., Schwartz, G. N., Karp, J. E., Burke, P. J., and Kaufmann, S. H. Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia. Blood, 85: 186-193, 1995.
28. Filipits, M., Suchomel, R. W., Zochbauer, S., Brunner, R., Lechner, K., and Pirker, R. Multidrug resistance-associated protein in acute myeloid leukemia: no impact on treatment outcome. Clin. Cancer Res., 3: 1419-1425, 1997.
29. Legrand, O., Simonin, G., Perrot, J-Y., Zittoun, R., and Marie, J-P. Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients. Blood, 91: 4480-4488, 1998.
30. Legrand, O., Simonin, G., Beauchamp-Nicoud, A., Zittoun, R., and Marie, J-P. Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia. Blood, 94: 1046-1056, 1999.
31. Löwenberg, B., Suciu, S., Archimbaud, E., Haak, H., Stryckmans, P., de Cataldo, R., Dekker, A. W., Berneman, Z. N., Thyss, A., Van der Lelie, J., Sonneveld, P., Visani, G., Fillet, G., Hayat, M., Hagemeijer, A., Solbu, G., and Zittoun, R. Mitoxantrone versus daunorubicin in induction-consolidation chemotheraypy: the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group. J. Clin. Oncol., 15: 872, 1998.
32. Vellenga, E., van Putten, W. L. J., Boogaerts, M. A., Daenen, S. M. G. J., Verhoef, G. E. G., Hagenbeek, A., Jonkhoff, A. R., Huijgens, P. C., Verdonck, L. F., van der Lelie, J., Schouten, H. C., Gmür, J., Wijermans, P., Gratwohl, A., Hess, U., Fey, M. F., and Löwenberg, B. Peripheral blood stem cell transplantation as an alternative to autologous marrow transplantation in the treatment of acute myeloid leukemia. Bone Marrow Transplant., 23: 1279-1282, 1999.
33. Zijlstra, J. G., de Vries, E. G. E., and Mulder, N. H. Multifactorial drug resistance in an Adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res., 47: 1780-1784, 1987.
34. Versantvoort, C. H. M., Withoff, S., Broxterman, H. J., Kuiper, C. M., Scheper, R. J., Mulder, N. H., and de Vries, E. G. E. Resistance associated factors in human small cell lung carcinoma GLC4 sublines with increasing Adriamycin resistance. Int. J. Cancer, 61: 375-380, 1995.
35. Boesen, J. J. B., Nooter, K., and Valerio, D. Circumvention of chemotherapy-induced myelosuppression by transfer of the MDR1 gene. Biotherapy, 6: 291-302, 1994.
36. Hendrikse, N. H., de Vries, E. G. E., Eriks-Fluks, L., van der Graaf, W. T. A., Hospers, G. A. P., Willemsen, A. T., Vaalburg, W., and Franssen, E. J. A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier. Cancer Res., 59: 2411-2416, 1999.
37. Jones, T. R., Zamboni, R., Belley, M., Champion, E., Charette, L., Ford-Hutchinson, A. W., Frenette, R., Gauthier, J-Y., Leger, S., Masson, P., McFarlane, S., Piechuta, H., Rokach, J., Williams, H., and Young, N. Pharmacology of L-660,711 (MK-571): a novel potent and selective leukotriene D4 receptor antagonist. Can. J. Physiol. Pharmacol., 67: 17-28, 1989.
38. Lorico, A., Rappa, G., Finch, R. A., Yang, D., Flavell, R. A., and Sartorelli, A. C. Disruption of the murine MRP (multidrug resistance protein) gene leads to increased sensitivity to etoposide (VP-16) and increased level of glutathione. Cancer Res., 57: 5238-5242, 1997.
39. Barlow, R. E., Bartholomew, D. J., Bremner, J. M., and Brunk, H. D. Statistical Inference under Order Restrictions. London: Wiley, 1972.
40. Kaplan, E. L., and Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457-481, 1958.
41. Van der Kolk, D. M., Vellenga, E., van der Veen, A. Y., Noordhoek, L., Timmer-Bosscha, H., Ossenkoppele, G. J., Raymakers, R., Müller, M., van den Berg, E., and de Vries, E. G. E. Deletion of the multidrug resistance protein MRP1 gene in acute myeloid leukemia: the impact on MRP activity. Blood, 95: 3514-3519, 2000.
42. Broxterman, H. J., Sonneveld, P., Feller, N., Ossenkoppele, G. J., Währer, D. C., Eekman, C. A., Schoester, M., Lankelma, J., Pinedo, H. M., Löwenberg, B., and Schuurhuis, G. J. Quality control of multidrug resistance assays in adult acute leukemia: correlation between assays for P-glycoprotein expression and activity. Blood, 87: 4809-4816, 1996.
43. Marie, J-P., Zhou, D. C., Gurbuxani, S., Legrand, O., and Zittoun, R. MDR1/P-glycoprotein in haematological neoplasms. Eur. J. Cancer, 32A: 1034-1038, 1996.
44. Bailly, J. D., Muller, C., Jaffrézou, J. P., Demur, C., Gassar, G., Bordier, C., and Laurent, G. Lack of correlation between expression and function of Pgp in acute myeloid leukemia cells. Leukemia (Baltimore), 9: 799-807, 1995.
45. Priebe, W., Krawczyk, M., Kuo, M. T., Yamane, Y., Savaraj, N., and Ishikawa, T. Doxorubicin- and daunorubicin-glutathione conjugates, but not unconjugated drugs, competively inhibit leukotriene C4 transport by MRP/GS-X pump. Biochem. Biophys. Res. Commun., 247: 859-863, 1998.
46. Ishikawa, T., Bao, J. J., Yamane, Y., Akimaru, K., Frindrich, K., Wright, C. D., and Kuo, M. T. Coordinated induction of MRP/GS-X pump and γ-glutamylcysteine synthetase by heavy metals in human leukemia cells. J. Biol. Chem., 271: 14981-14988, 1996.
47. Tew, K. D., O'Brien, M., Laing, N. M., and Shen, H. Coordinate changes in expression of protective genes in drug-resistant cells. Chem. Biol. Interact., 112: 199-211, 1998.
48. Zhou, D. C., Simonin, G., Faussat A. M., Zittoun, R., and Marie, J-P. Effect of the multidrug inhibitor GG918 on drug sensitivity of human leukemic cells. Leukemia (Baltimore), 11: 1516-1522, 1997.
49. Consoli, U., Van, N. T., Neamati, N., Mahadevia, R., Beran, M., Zhao, S., and Andreeff, M. Cellular pharmacology of mitoxantrone in P-glycoprotein-positive and -negative human myeloid leukemic cell lines. Leukemia (Baltimore), 11: 2066-2077, 1997.
50. Asschert, J., de Vries, E. G. E., van der Kolk, D. M., Müller, M., and Vellenga, E. The combined effects of IL-3 and PSC833 on daunorubicin- and mitoxantrone cytotoxicity in two growth factor-dependent leukemic cell lines. Leukemia (Baltimore), 11: 680-686, 1997.
51. Cole, S. P., Sparks, K. E., Fraser, K., Loe, D. W., Grant, C. E., Wilson, G. M., and Deeley, R. G. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res., 54: 5902-5910, 1994.
52. Futscher, B. W., Abbaszadegan, M. R., Domann, F., and Dalton, W. S. Analysis of MRP mRNA in mitoxantrone-selected, multidrug-resistant human tumor cells. Biochem. Pharmacol., 47: 1601-1606, 1994.
53. Schneider, E., Horton, J. K., Yang, C. H., Nakagawa, M., and Cowan, K. H. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Cancer Res., 54: 152-158, 1994.
54. Te Boekhorst, P. A. W., de Leeuw, K., Schoester, M., Wittebol, S., Nooter, K., Hagemeijer, A., Löwenberg, B., and Sonneveld, P. Predominance of functional multidrug resistance (MDR1) phenotype in CD34+ acute myeloid cells. Blood, 10: 3157-3162, 1993.
55. Sonneveld, P., Schoester, M., and de Leeuw, K. Clinical modulation of multidrug resistance in multiple myeloma: effect of cyclosporin on resistant tumor cells. J. Clin. Oncol., 12: 1584-1591, 1994.
56. Sonneveld, P., Marie, J-P., Huisman, C., Vekhoff, A., Schoester, M., Faussat, A. M., van Kapel, J., Groenewegen, A., Charnick, S., Zittoun, R., and Löwenberg, B. Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma: a Phase I study. Leukemia (Baltimore), 10: 1741-1750, 1996.
57. Advani, R., Saba, H. I., Tallman, M. S., Rowe, J. M., Wiernik, P. H., Ramek, J., Dugan, K., Lum, B., Villena, J., Davis, E., Paietta, E., Litchman, M., Sikic, B. I., and Greenberg, P. L. Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valdospar). Blood, 3: 787-795, 1999.
58. Damiani, D., Michieli, M., Ermacora, A., Russo, D., Fanin, R., Zaja, F., Baraldo, M., Pea, F., Furlanut, M., and Baccarani, M. Adjuvant treatment with cyclosporin A increases the toxicity of chemotherapy for remission induction in acute non-lymphocytic leukemia. Leukemia (Baltimore), 12: 1236-1240, 1998.
59. Kornblau, S. M., Estey, E., Madden, T., Tran, H. T., Zhao, S., Consoli, U., Snell, V., Sanchez-Williams, G., Kantarjian, H., Keating, M., Newman, R. A., and Andreeff, M. Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia. J. Clin. Oncol., 15: 1796-1802, 1997.